Dr. David A. Katzka is a recognized authority, both in the clinical and research arenas, on eosinophilic esophagitis, esophageal motility disorders, gastroesophageal reflux, Barrett’s esophagus, and unusual esophageal diseases. Dr. Katzka now brings his expertise and 35 years of experience in the treatment and understanding of esophageal diseases to NewYork-Presbyterian/Columbia University Irving Medical Center, where he is leading the Esophagology and Swallowing Center.
A prolific researcher, Dr. Katzka has greatly influenced progress in the field, with more than 350 publications to his name. In July 2021, he completed a five-year role as Program Director/Principal Investigator for the Consortium of Eosinophilic Gastrointestinal Disease Researchers-Clinical Trial 2: Six Food vs One Food Eosinophilic Esophagitis Elimination Diet (SOFEED) followed by Swallowed Glucocorticoid Trial. Since 2009, Dr. Katzka has been a member of and continues to serve on the Editorial Board of Clinical Gastroenterology and Hepatology. He also serves on the Editorial Boards of the Gastroenterology, Alimentary Pharmacology and Therapeutics, The American Journal of Gastroenterology, and as an editor/reviewer of Diseases of the Esophagus. His honors and awards include the Distinguished Clinician Award presented by the American Gastroenterological Association (AGA) and, most recently, Dr. Katzka was honored with the 2022 AGA Institute Council Section Research Mentor Award, which acknowledges the achievements of AGA members who serve the gastroenterology and hepatology community as outstanding mentors in research.
Dr. Katzka joins NewYork-Presbyterian/Columbia from Mayo Clinic College of Medicine and Science where he was Professor of Medicine and Head of the Esophageal Interest Group. He was also a Consultant for the Division of Gastroenterology and Hepatology and held Master's Faculty Privileges in Clinical and Translational Science at the Mayo Clinic. Prior, he was a Professor of Medicine at the University of Pennsylvania.
